Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database.
about
Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug AdministrationA systematic review of comparative efficacy of treatments and controls for depressionEfficacy of antidepressants in adultsAntidepressant drug effects and depression severity: a patient-level meta-analysisThe 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouseInnovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?The risks of selective serotonin reuptake inhibitor use in infertile women: a review of the impact on fertility, pregnancy, neonatal health and beyondRisk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkersConsistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depressionSelective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential AnalysisVocal acoustic biomarkers of depression severity and treatment responseVoice acoustic measures of depression severity and treatment response collected via interactive voice response (IVR) technology.Are we drawing the right conclusions from randomised placebo-controlled trials? A post-hoc analysis of data from a randomised controlled trial.Placebo, prozac and PLoS: significant lessons for psychopharmacology.Behavior analysis in the era of medicalization: the state of the science and recommendations for practitioners.Are antidepressants clinically useful? Conclusion of a decade of debate.Anchoring perceptions of clinical change on accurate recollection of the past: memory enhanced retrospective evaluation of treatment (MERET).Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice GuidelineInforming the development of services supporting self-care for severe, long term mental health conditions: a mixed method study of community based mental health initiatives in England.Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials.Magnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interviews (SIGMA-RAPS) compared to trials using traditional semi-structured interviews.Toward personalizing treatment for depression: predicting diagnosis and severity.Antidepressants versus placebo in major depression: an overviewAustralian and New Zealand clinical practice guidelines for the treatment of depression.Homeopathy for depression--DEP-HOM: study protocol for a randomized, partially double-blind, placebo controlled, four armed studyCorticosterone facilitates fluoxetine-induced neuronal plasticity in the hippocampus.Homeopathic Individualized Q-Potencies versus Fluoxetine for Moderate to Severe Depression: Double-Blind, Randomized Non-Inferiority TrialThe treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placeboPlacebo eff ects in psychiatry: mediators and moderators.Challenges in the development of clinical trials for major depressive disorder: lessons learned from trials in minor depression.Age and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicineClinical subtypes of premenstrual syndrome and responses to sertraline treatmentNature of the placebo effect.Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depressionBaseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trialEffects of anxiety on the long-term course of depressive disordersRethinking recommendations for screening for depression in primary care.Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good.Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy.Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?
P2860
Q21092366-167E5D4D-F530-4C0B-B793-56F5DFED832EQ21134116-4CC2156A-9FAB-4519-97D6-39F0FCBE4FCAQ24555325-AF566D68-0EEB-474E-9495-FCFF44ED80ADQ24598580-CEB1E781-4EAA-4C5B-837C-C9616FDB7C62Q26849351-15AC334F-F71B-4262-901A-945959BA6EC3Q26996411-D504DBEF-0528-4A2D-82A1-B20F3AC30CC5Q27010327-DC97551D-7CBE-4854-86DD-AE68D9612151Q27023402-DDD850DE-DAB2-4B81-B4BB-25CF48978C82Q28550946-38F617E3-76AB-4FFC-807A-10AEBD5D5E79Q28736049-F9915CF8-AE8A-4326-84E0-51F3172AF7FEQ30448566-1DF42F3D-05CC-441A-AAA9-D79F83ACB899Q30477558-BF27C72E-1567-4D64-912A-1CECCF36DB66Q33472994-AF364DC4-5A6A-4819-A573-D8B3C9650766Q33613487-70404BB9-3A88-4EF0-A7E3-34C24872E1D3Q33810992-B0F0F8F4-7DA4-4BCA-9A00-02833047A976Q33915538-F921ED9F-CE74-461F-A4E0-D1E2C9B05CF7Q34068868-9981F034-1230-45FE-B0F8-C5F2C45CCA28Q34247551-3BD4E470-4130-4672-AD20-D81D16CA83B5Q34329489-B26B6BC4-46B1-4A44-A4DF-CE74C565E6A1Q34355963-3C3BB3BC-64E1-4AE3-8287-EEAF50607294Q34396650-2A0FA6EB-8055-4397-9C19-275A71F6BC42Q34430123-5D9320C2-B58B-4ED1-ADBC-546A6357BD00Q34495779-A9B8A023-4BE1-46F0-BF7E-4C569C972CFAQ34548787-8F7DA950-A256-4EAD-9FCD-43E1013079CAQ34610907-6E2A5DBB-B0CF-4780-AC37-E19F93F433FBQ34722951-5B076EDA-9DD5-4759-B10B-4346FA6E5F0AQ35105942-130C009C-3BD6-4272-ADC0-A590284708EEQ35108088-00893C0F-5FAA-4CCA-AACE-5C7307899B2DQ35207492-32D224CA-5673-4598-91A0-AC11092EB667Q35236533-D16654D1-5869-4A58-9A64-9DEC41AE9311Q35513153-EDEEDB71-4387-4CDF-880E-4818D2E8C95AQ35569566-A044D796-6C6C-4FB3-94C0-3AD1A0BEBCF9Q35616847-2D9BA46B-D66C-495F-95DD-2B31CC2DAC06Q35679916-2C553589-3E49-47A7-BC2E-B3FB80D2486DQ35740330-5B2A5B7F-20DF-4204-904A-C9060AE21B2AQ35791605-6B061D5F-76BB-480D-BC1A-F3743310ACCCQ35794662-E85C5429-19B6-4CE6-B642-0A31EA67745FQ35907475-A23784B3-F27D-4BAC-A6D1-12EA428CBF8BQ36007894-C1794433-B30B-4A90-889B-B18831673CA7Q36022784-569500DC-24D3-442C-820F-194AB78FA98F
P2860
Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Severity of depression and res ...... Drug Administration database.
@en
type
label
Severity of depression and res ...... Drug Administration database.
@en
prefLabel
Severity of depression and res ...... Drug Administration database.
@en
P2093
P1476
Severity of depression and res ...... Drug Administration database.
@en
P2093
Robyn M Leventhal
Shirin R Khan
Walter A Brown
P356
10.1097/00004714-200202000-00007
P407
P577
2002-02-01T00:00:00Z